CommercialDocumentationMedium impact
08.02.07d, Glofitamab-gxbm (Columvi)
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.02.07d has been updated with new medical necessity criteria for Glofitamab-gxbm (Columvi), a pharmaceutical treatment. The billing team must implement these updated criteria to ensure claims meet coverage requirements and avoid denials.
Action Required
By 2025-07-28: Billing team must review the complete medical necessity criteria in policy 08.02.07d and update prior authorization protocols in the billing system. Coordinate with providers to ensure all Glofitamab-gxbm (Columvi) claims include documentation supporting the updated medical necessity criteria. Update claim submission checklists and denial management workflows to reflect new requirements. Claims submitted without proper documentation of medical necessity will be subject to denial. Reference the full policy at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-07d for specific criteria details.